Press releases
Full text versions of press releases are only available in Swedish
2023-05-31
BULLETIN FROM ONCOZENGE´S AGM ON MAY 31, 2023
Read More
2023-05-16
ONCOZENGE INTERIM REPORT JANUARY-MARCH 2023
Read More
2023-05-09
ONCOZENGE RECEIVES RESPONSES FROM REGULATORY AUTHORITIES IN EUROPE AND THE US
Read More
2023-05-03
ONCOZENGE ANNUAL REPORT 2022
Read More
2023-04-28
NOTICE OF ANNUAL GENERAL MEETING FOR ONCOZENGE AB
Read More
2023-02-13
ONCOZENGE AB YEAR-END REPORT FOR THE FINANCIAL YEAR 2022
Read More
2022-11-15
ONCOZENGE AB INTERIM REPORT JANUARY - SEPTEMBER 2022
Read More
2022-10-21
ONCOZENGE´S NOMINATION COMMITTEE APPOINTED
Read More
2022-08-25
GOOD RESULTS FROM ONCOZENGE'S TOXICITY AND SAFETY STUDY FOR BUPIZENGE®
Read More
2022-08-16
ONCOZENGE AB INTERIM REPORT JANUARY - JUNE 2022
Read More
2022-06-30
BULLETIN FROM ONCOZENGE AGM ON JUNE 30, 2022
Read More
2022-06-08
ONCOZENGE ANNUAL REPORT 2021
Read More
2022-05-31
NOTICE OF ANNUAL GENERAL MEETING IN ONCOZENGE AB
Read More
2022-05-17
ONCOZENGE AB INTERIM REPORT JANUARY - MARCH 2022
Read More
2022-04-22
ONCOZENGE BEGINS REFORMULATION OF BUPIZENGE®, INITIATES PROCESS TO BROADEN THE COMPANY'S OPERATIONS AND POSTPONES THE ANNUAL GENERAL MEETING
Read More
2022-04-12
ONCOZENGE DISCONTINUE THE PLANNED PATIENT STUDY WITH BUPIZENGE®
Read More
2022-02-15
ONCOZENGE YEAR-END REPORT FOR THE FINANCIAL YEAR 2021
Read More
2022-02-15
ONCOZENGE INITIATES TOXICITY STUDY AND ANNOUNCES MODIFICATION TO THE CLINICAL PLAN
Read More
2021-11-07
BULLETIN FROM ONCOZENGE´S EXTRAORDINARY GENERAL MEETING ON DECEMBER 7, 2021
Read More
2021-11-22
PAUL DE POTOCKI NEW CEO FOR ONCOZENGE AB
Read More
2021-11-22
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ONCOZENGE AB
Read More
2021-11-16
ONCOZENGE AB INTERIM REPORT JANUARY - SEPTEMBER 2021 IN SUMMARY
Read More
2021-11-04
ONCO ZENGE´S NOMINATION COMMITTEE APPOINTED
Read More
2021-09-29
THE SWEDISH TAX AGENCY HAS PUBLISHED A NOTIFICATION ON THE ACQUISITION COST OF SHARES REGARDING MOBERG PHARMA´S DISTRIBUTION OF SHARES IN ONCOZENGE AB
Read More
2021-08-17
ONCOZENGE AB INTERIM REPORT FOR JANUARY - JUNE 2021
Read More
2021-08-10
ONCOZENGE AB INTERIM REPORT FOR JANUARY - JUNE 2021 TO BE PUBLISHED ON AUGUST 17 - INVITATION TO TELECONFERENCE
Read More
2021-05-25
BULLETIN FROM ONCOZENGE AGM ON MAY 25, 2021
Read More
2021-05-18
ONCOZENGE AB INTERIM REPORT JANUARY-MARCH 2021
Read More
2021-04-26
NOTICE OF ANNUAL GENERAL MEETING OF ONCOZENGE AB (PUBL)
Read More
2021-04-12
ONCOZENGE APPOINTS DR. MARKUS JERLING TO CHIEF MEDICAL OFFICER
Read More
2021-03-18
LAST DAY FOR TRADING IN BTA
Read More
2021-03-09
ONCOZENGE RIGHTS ISSUE HEAVILY OVERSUBSCRIBED AND NO ISSUE GUARANTEES HAVE BEEN EXERCISED
Read More
2021-02-19
THE SUBSCRIPTION PERIOD FOR ONCOZENGE´S RIGHTS ISSUE BEGINS TODAY
Read More
2021-02-15
THE LAST DAY FOR TRADING IN THE RIGHT TO RECEIVE SUBSCRIPTION RIGHTS IS TODAY, FEBRUARY 15, 2021
Read More
2021-02-12
TRADING IN ONCOZENGE´S SHARE ON THE NASDAQ FIRST NORTH GROWTH MARKET BEGINS TODAY
Read More
2021-02-10
ONCOZENGE HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET
Read More
2021-02-08
CORRECTION REGARDING ISIN CODE FOR THE SHARE IN THE PROSPECTUS
Read More
2021-02-08
ONCOZENGE HAS OBTAINED A CONDITIONAL APPROVAL FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET AND PUBLISHES PROSPECTUS
Read More
2021-01-29
ANNOUNCEMENT OF TERMS FOR THE FULLY GUARANTEED RIGHTS ISSUE IN ONCOZENGE, TIMETABLE FOR THE LISTING AND RECORD DATE FOR LEX ASEA
Read More
2020-12-16
ONCOZENGE EXPANDS THE BOARD WITH HILDE FURBERG
Read more
2020-11-30
MOBERG PHARMA OBTAINS POSITIVE DECISION FROM THE SWEDISH TAX AGENCY REGARDING THE LEX ASEA DISTRIBUTION OF THE SHARES IN ONCOZENGE
Read more
2020-11-23
INVITATION TO MARKET UPDATE IN MOBERG PHARMA ON NOVEMBER 25TH
Read more
2020-11-16
ONCOZENGE SECURES APPROXIMATELY SEK 70 MILLION IN FINANCING AHEAD OF SPIN-OFF AND SEPARATE LISTING
Read more
2020-11-06
MOBERG PHARMA INTENDS TO DISTRIBUTE AND SEPARATELY LIST BUPIZENGE[®] (BUPI)
Read more